Answers are grounded in this paper and cite their sources.
Retrospective registry study forecasts incidence and survival for meningioma and glioblastoma, suggesting increased resources are needed.
e14052 Background: Forecasting future central nervous system tumor burden is needed for workforce planning & trial feasibility. We quantified U.S. incidence trends, projected incidence to 2050, & evaluated overall survival (OS) for meningioma & glioblastoma (GBM). Methods: Retrospective registry study using SEER*Stat case listings (Nov 2024 submission). We identified first primary GBM (ICD-O-3 9440/3; SEER Research Data, 17 registries; 2000-2022) & first meningioma (benign/borderline/malignant; SEER Research Limited-Field Data, 21 registries; 2000-2022). Age-adjusted incidence (per 100,000; 2000 U.S. standard) was modeled with log-linear annual percent change (APC) in prespecified primary windows (GBM 2000-2022; meningioma 2004-2022). Projections extrapolated fitted trends from 2022 to estimate 2050 incidence. OS was estimated by Kaplan-Meier & modeled with Cox regression adjusted for age group, sex, & race/ethnicity (missing retained as a category). SEER data are de-identified; IRB review not required. Analyses were performed in Python (Anaconda). Results: We analyzed 48,019 GBM and 261,643 meningioma cases. GBM incidence was stable overall (APC 0.12%/y; 95% CI -0.03 to 0.28; p=0.128) but increased in females (0.27%/y; 0.07 to 0.47; p=0.014). Meningioma incidence increased substantially (APC 2.62%/y; 2.14 to 3.10; p<0.001). Projected 2050 incidence rose modestly for GBM (3.00 in 2022 to 3.19 per 100,000) but more than doubled for meningioma (11.50 to 25.55); a sensitivity including Illinois was similar. GBM median OS was 9 months. Death occurred in 90.4% of GBM & 32.0% of meningioma patients. Male sex was associated with higher mortality (GBM HR 1.07, 95% CI 1.05-1.09; meningioma HR 1.50, 1.47-1.52; both p<0.001). Conclusions: In SEER, GBM incidence is largely stable, whereas meningioma incidence is rising steeply and is projected to drive a substantially larger U.S. incidence burden by 2050. These findings support planning for increased diagnostic/surgical capacity and long-term survivorship resources for meningioma while sustaining therapeutic innovation for GBM. Key incidence, projection, and survival endpoints. Measure GBM (overall) GBM (female) Meningioma Cases, n 48,019 19936 261,643 APC (%/y), primary window 0.12 (-0.03 to 0.28); p=0.128 0.27 (0.07 to 0.47); p=0.128 2.62 (2.14 to 3.10); p<0.001 Age-adjusted incidence 2022 (per 100,000) 3.00 2.40 11.50 Projected incidence 2050 (per 100,000; % change) 3.19 (+6.3%) 2.64 (+10%) 25.55 (+122.2%) Male vs female mortality (Cox HR, 95% CI) 1.07 (1.05-1.09) - 1.50 (1.47-1.52) APC, annual percent change; CI, confidence interval; HR, hazard ratio. Incidence rates are per 100,000 & age-adjusted to the 2000 U.S. standard population. APC from log-linear models (GBM 2000–2022; meningioma 2004–2022).Cox models adjusted for age group, sex, & race/ethnicity (missing retained as category).
No takes yet. Share an insight, caveat, or question.
Mobin Mobadersani (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: